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Abstract 
Immunotherapy with anti-PD-1 antibody preliminarily showed promising efficacy for 
treating esophageal squamous cell carcinoma (ESCC). Herein, we used tissue 
microarrays and immunohistochemically analyzed PD-L1 and various 
tumor-infiltrating immune cells (TIICs) in specimens from 196 ESCC patients who had 
undergone curative resection without preoperative therapy. PD-L1 expressions in 
tumor cells (TCs) and TIICs, as well as infiltration of lymphocytes (CD4+, CD8+, 
FOXP3+, and PD-1+) and macrophages (CD68+ and CD204+), were evaluated. PD-L1 
was expressed in TCs of 18.4% and in TIICs of 83.3% of these patients. PD-L1 
expressions in TCs and TIICs were associated with significant infiltration of various 
TIIC types, especially CD8+ cells. PD-L1 expressions in both TCs and TIICs were 
significantly associated with favorable overall survival, and combining their levels 
enhanced prognostic accuracy. Prognostic impacts of PD-L1 expressions in TCs and 
TIICs, abundant PD-1+ cell infiltration, a high CD8+/FOXP3+ ratio, and the 
CD8+/CD204+ ratio remained significant after adjusting for clinicopathological factors. 
In conclusion, PD-L1 expression reflects anti-tumor immunity, and PD-1/PD-L1 
expression and the ratio of infiltrating effector to immune suppressor cells have 
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prognostic value. Therapeutic strategies inhibiting the PD-1/PD-L1 signal and immune 
suppressor cells are anticipated in ESCC patients. 
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Introduction 
 Squamous cell carcinoma is the predominant histological type of esophageal 
cancer worldwide, though the incidence of esophageal adenocarcinoma exceeds that of 
squamous cell carcinoma in the UK, certain other western European countries, and the 
United States [1]. Smoking and alcohol consumption, known as major risk factors for 
esophageal squamous cell carcinoma (ESCC), have synergistic effects on 
carcinogenesis, which are shared with head and neck and also lung cancers [2-4]. 
Chronic exposure to carcinogens such as nitrosamine related to smoking and the 
alcohol metabolite aldehyde cause DNA damage and multiple genetic changes [5, 6]. 
Though no driver gene mutations have yet been detected in ESCC, among solid tumors 
the somatic mutation rate in ESCC is relatively high [7, 8]. 
 Recent advances in cancer immunology have revealed the importance of 
signaling between Programmed Death–1 (PD-1), expressed on antigen-experienced T 
cells, and its ligand PD-L1, expressed on antigen presenting cells and tumor cells 
(TCs) [9]. Anti-PD-1 or anti-PD-L1 antibodies have clinically benefitted patients with 
some solid cancers in early clinical trials [10-12]. In a recent phase 3 trial, a favorable 
response and survival outcomes were obtained with an anti-PD-1 monoclonal antibody, 
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nivolumab, in advanced squamous-cell non-small-cell lung cancer which is genetically 
similar to ESCC [13, 14]. In addition, a favorable response and durable efficacy of 
anti-PD-1 monoclonal antibodies for ESCC were also demonstrated in early clinical 
trials [15, 16]. In the context of biomarker analysis, PD-L1 expression in TCs, that in 
tumor-infiltrating immune cells (TIICs), and a high level of CD8+ T cell infiltration 
have been shown, in several clinical trials testing anti-PD-1 and anti-PD-L1 antibody 
therapy, to be potential predictive biomarkers of clinical efficacy [17-20]. 
 PD-L1 is expressed on TCs in ESCC and other solid tumors [21, 22]. Recently, 
high mutation burdens in tumors were reported to be associated with a clinical benefit 
of PD-1 blockade [23]. Given the relatively high mutation burden in ESCC [7, 8], 
PD-1/PD-L1 blockade shows promise for treating ESCC. The importance of the 
immune response to cancer has been studied in terms of infiltration of lymphocytes 
and macrophages in ESCC [24-26]. To date, no study has explored the associations of 
PD-L1 expressions in TCs and TIICs and the infiltration of effector cells or immune 
suppressor cells (regulatory T cells and M2 macrophages). 
 We performed the present immunohistochemical (IHC) study using surgically 
resected specimens from a large cohort of treatment-naïve patients with ESCC to 
identify and quantify PD-L1 expressions in tumors and their associations with 
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anti-tumor immune responses. The survival impacts of various immunological factors 
were also assessed. 
 
Materials and Methods 
Patients and specimens 
 Among the 372 patients with no prior therapy who underwent surgical resection 
of esophageal cancer between 2000 and 2011 at the National Cancer Center Hospital 
East, Kashiwa, Japan, 196 were consecutively enrolled in this study based on the 
following selection criteria: i) histologically confirmed squamous cell carcinoma, ii) 
pathological T factor of at least T2 according to the  TNM classification [27], iii) 
complete resection performed, iv) no in-hospital death after surgery, and v) sufficient 
formalin-fixed paraffin-embedded surgically resected tissue sample amounts available. 
Clinical and pathological information was collected from medical records including the 
pathology report for each subject. The study protocol was approved by the institutional 
review board of the National Cancer Center in October 2014 (2014-124). The study 
was carried out according to the Epidemiological Study Guideline of the Ministry of 
Health, Labour and Welfare of Japan. We disclosed the study design on the National 
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Cancer Center website and gave the relatives of deceased patients the opportunity to 
decline participation.  
 After reviewing hematoxylin and eosin (H&E) slides of the archived primary 
tumors, a representative block was selected in each case. A 2.0-mm in diameter tumor 
core was obtained from the center of the selected block, using a manual tissue arrayer 
(Azumaya Ika Kikai, Tokyo, Japan). These cores were assembled in a tissue 
microarray (TMA) format, and paraffin-embedded TMA blocks were then cut into 
4-µm sections and placed on silicon-coated slides for IHC staining. 
Immunohistochemistry 
 The primary antibodies used for IHC and the IHC assay are described in 
Supplementary Material 1. For CD4, CD8 and CD68, IHC was performed employing 
ready-to-use antibodies and the fully automated Ventana Benchmark ULTRA platform 
(Ventana, Tucson, AZ, USA) according to the manufacturer’s instructions. For CD204, 
IHC was performed using the Ventana Benchmark ULTRA platform 
semi-automatically with manual application of the primary antibody. For FOXP3, 
PD-1 and PD-L1, IHC was performed manually. 
Evaluation of PD-L1 expression and tumor infiltrating immune cells 
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 After IHC, the slides were scanned and the microscopic images were imported 
as digital photo files using the NanoZoomer Digital Pathology (NDP) system 
(Hamamatsu Photonics, Hamamatsu, Japan). PD-L1 expression was identified by two 
independent observers (KH and SF) blinded to all of the clinical data. To assess PD-L1 
in TCs, the proportion of TCs with membrane staining was scored as <1%, 1-4%, 5-9%, 
10%, and then at 10% intervals up to ≥ 50%. When the difference between the 
assessments of the two pathologists was one level or greater, the slide was reviewed 
jointly and a single consensus score was established. Finally, PD-L1 positive 
expression in TCs was defined as the presence of ≥ 1% of TCs with membrane staining 
based on the hazard ratio for OS (Supplementary Figure 1). PD-L1 expression in TIICs 
was determined qualitatively to be either positive (any expression of PD-L1 in TIICs in 
the core) or negative (no staining). 
 To quantitatively evaluate each TIIC type, the entire tumor core was reviewed 
using NDP view at a magnification of × 200 and 4 independent areas with a size of 
0.0625 mm2, containing the greatest abundance of TIICs in the tumor nest, were 
selected. After counting the TIICs in each selected area using NDP view at a 
magnification of × 400, numbers of the respective TIICs per square millimeter 
calculated from the total number in the 4 selected areas were presented. We calculated 
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ratios of infiltrating effector cells to immune suppressor cells, such as CD8+/FOXP3+ 
(CD8+ cell count divided by FOXP3+ cell count) and CD8+/CD204+, and ratios of the 
infiltrating immune suppressor cells to the corresponding whole cell populations, such 
as FOXP3+/CD4+ and CD204+/CD68+, were also determined. 
Statistical analysis 
 The numbers of each TIIC type were compared according to PD-L1 expression 
status (positive/negative), in TCs and TIICs, using the Mann-Whitney U test. The 
Chi-square test was applied to assess the relationships between clinicopathological 
factors and PD-L1 expressions in TCs and TIICs, and the McNemar test was used to 
compare the proportions positive for PD-L1 expression between TCs and TIICs. OS 
was defined as the period from the date of surgery until the date of death from any 
cause. Patients were censored at the time of their last follow-up, if they were alive. OS 
rates were estimated using the Kaplan-Meier method, and were compared using the 
log-rank test. Immunological factors other than PD-L1 expression status were 
dichotomized according to their median values (≥ median / < median). 
Univariate and multivariate Cox proportional hazards models were used to 
examine the associations of clinicopathological factors with OS. The impacts of 
immunological factors (PD-L1 expressions in TCs and TIICs, number of each type of 
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TIIC, and TIIC ratios [CD8+/FOXP3+, CD8+/CD204+, FOXP3+/CD4+ and 
CD204+/CD68+]) on OS were first examined with univariate Cox regression models. 
Next, the impact of each immunological factor on OS was assessed by adding each 
factor to the multivariate model which contained the possibly confounding 
clinicopathological factors such as age, gender, smoking status, alcohol consumption, 
location, pT factor, lymph node metastasis, histological grade, lymphatic invasion, and 
venous invasion. All statistical analyses were performed using IBM SPSS statistics 20 
(IBM Japan Ltd., Tokyo, Japan). All P values were two-sided, with a significance level 
of 0.05. 
 
Results 
PD-L1 expressions in ESCC and TIICs 
 The clinicopathological characteristics of our patients are listed in Table 1. None 
of the patients in this study had distant organ metastasis or had received immune 
therapies, such as immune checkpoint inhibitors and immune cell therapy. 
Representative cases with PD-L1 expression in TCs and TIICs are shown in Figure 1. 
PD-L1 expression was positive in TCs from 36 patients (18.4%, 95% confidence 
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interval [CI]: 13.2-24.5). PD-L1 expression was positive in TIICs from 119 patients 
(60.7%, 95% CI: 53.5-67.6). Among patients showing PD-L1 positive in TCs, 83.3% 
demonstrated PD-L1 positive in TIICs, a significantly higher percentage than that in 
patients whose TCs were PD-L1 negative (P < 0.001) (Table 2). In total, 125 patients 
(63.8%, 95% CI: 56.6-67.6) had TC and/or TIIC positive for PD-L1. The only 
clinicopathological characteristic significantly associated with PD-L1 expression status, 
specifically that in TCs, was age (Table 1). 
PD-L1 expression and infiltration of TIICs 
 IHC results of representative cases with each TIIC type are shown in 
Supplementary Figure 2. Figure 2 demonstrates the relationship between PD-L1 
expression status in TCs and TIICs and the number and ratio of each TIIC type. The 
numbers of all TIIC types evaluated were higher in subgroups with PD-L1 positive in 
TCs and in TIICs than in subgroups with PD-L1 negative in TCs and in TIICs. This 
tendency was especially strong for CD8+ cells. The CD8+/FOXP3+ and CD8+/CD204+ 
ratios were also higher in subgroups with PD-L1 positive in TCs and in TIICs. In 
contrast, the FOXP3+/CD4+ ratio tended to be lower, though not significantly, in 
subgroups with PD-L1 positive in TCs and in TIICs. 
Survival analyses according to immunological factors 
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 The median follow-up time of the censored cases was 5.5 years (range, 0.1-10.6) 
from the date of surgery. The overall survival (OS) curves according to PD-L1 
expression are presented in Figure 3. Patients with PD-L1 positive in TCs 
demonstrated significantly better OS than those with PD-L1 negative in TCs (P = 
0.019). Patients with PD-L1 positive in TIICs had significantly better OS than those 
with PD-L1 negative in TIICs (P = 0.041). We divided patients into three groups 
according to the PD-L1 expression status of their TCs and TIICs: both PD-L1 positive 
(group 1), either one PD-L1 positive (group 2), and both PD-L1 negative (group 3). 
The separate OS curves for these 3 groups revealed a statistically significant difference 
only between groups 1 and 3 (P = 0.097 between groups 1 and 2, P = 0.098 between 
groups 2 and 3, P = 0.007 between groups 1 and 3). 
 The OS curves according to TIIC ratios are presented in Figure 4. Patients with a 
high CD8+/FOXP3+ ratio had significantly better OS than those with a low 
CD8+/FOXP3+ ratio (P = 0.010). Patients with a high CD8+/CD204+ ratio had 
significantly better OS than those with a low CD8+/CD204+ ratio (P = 0.024). In 
contrast, patients with a high FOXP3+/CD4+ ratio showed significantly poorer OS than 
those with a low FOXP3+/CD4+ ratio (P = 0.036). Although the OS curves were drawn 
separately according to CD204+/CD68+ ratios, the difference did not reach statistical 
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significance (P = 0.314). Among each TIIC type assessed, prognostic significance was 
demonstrated in CD8+ cells (P = 0.040) and PD-1+ cells (P = 0.032) (Supplementary 
Figure 3).  
Multivariate analyses for survival outcomes 
 The results of univariate and multivariate survival analyses are presented in 
Table 3. Both TCs (HR 0.461, 95% CI: 0.246-0.864, P = 0.016) and TIICs (HR 0.590, 
95% CI: 0.394-0.884, P = 0.010) being PD-L1 positive was significantly associated 
with longer OS in multivariate analysis even after adjusting for potentially 
confounding clinicopathological factors. A high CD8+/FOXP3+ ratio (HR 0.617, 95% 
CI: 0.413-0.923, P = 0.019) and a high CD8+/CD204+ ratio (HR 0.650, 95% CI: 
0.439-0.962, P = 0.031) were also significantly associated with longer OS, although 
none of the TIIC types individually showed a significant association with OS except 
for PD-1+ cells (HR 0.579, 95% CI: 0.387-0.865, P = 0.008). We explored OS based on 
TIICs in the stroma by focusing on factors significantly impacting OS in the tumor nest 
assessment (CD8+/FOXP3+, CD8+/CD204+, and PD-1+). None significantly impacted 
OS in multivariate analyses (Supplementary Figure 4). 
Discussion 
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 We clarified PD-1 and PD-L1 expressions, the associations between PD-L1 
expression and various immune cells, and the prognostic relevance of these factors 
employing IHC with tissue microarrays for 196 ESCC cases who had received neither 
preoperative neoadjuvant therapy nor post-recurrence immunotherapy. 
 Reports of PD-L1 expression in ESCC are limited. PD-L1 positive rates in TCs 
were reported to be 41.9% by Ohigashi et al and 84.5% by Chen et al [21, 22], though 
PD-L1 expressions on the plasma membrane and in the cytoplasm were defined as 
positive in their studies. Mechanistically, PD-L1 is a type I transmembrane molecule 
expressed on TCs and binds to its receptor, PD-1, which is expressed on the plasma 
membranes of activated T cells [28]. Furthermore, PD-L1 expression on the plasma 
membrane has been evaluated as a biomarker candidate in recent clinical trials of 
anti-PD-1 or anti-PD-L1 antibody therapy [17-19]. Accordingly, we evaluated PD-L1 
expression on the plasma membranes of TCs employing a cut-off value of 1% based on 
the sensitivity test assessing hazard ratios for OS, and demonstrated the positive rate to 
be 18.4% in our patients. The positive rate of 63.8% for PD-L1 expression in TCs 
and/or TIICs demonstrated herein was compatible with the results of a phase 1 trial for 
esophageal cancer [15].  
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 Marked infiltration of CD8+ cells into a PD-L1 positive tumor has been reported 
for several cancers including ESCC [21, 29, 30]. In this study, abundant infiltrations of 
CD8+ and PD-1+ cells were associated with PD-L1 expression in TCs and TIICs, 
observations in line with the theory that PD-L1 expression is induced by several 
pro-inflammatory factors, such as IFNγ and TNFα produced by activated T cells [31, 
32], and that the PD-1/PD-L1 pathway plays a role in suppressing activated T cells in 
the periphery. In addition, marked infiltrations of immune suppressor cells such as 
regulatory T cells (FOXP3+) and M2 macrophages (CD204+) were also associated with 
PD-L1 expression in both TCs and TIICs. These results indicate that PD-L1 expression 
in TCs and/or TIICs reflects a highly activated immune response to tumors and also the 
adaptive immune resistance which develops as a consequence. In contrast, significant 
associations of positivity for PD-L1 expression with the CD8+/FOXP3+ and 
CD8+/CD204+ ratios, as well as a trend for an inverse association of PD-L1 expression 
with the FOXP3+/CD4+ ratio, were observed, suggesting PD-L1 expression to be 
associated with the balance between infiltrating effector cells and immune suppressor 
cells. 
 The prognostic significance of PD-L1 expression in TCs remains controversial. 
Previous studies of ESCC demonstrated an association between PD-L1 expression and 
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poor outcomes [21, 22]. However, we found PD-L1 expression to be a factor 
predicting favorable OS. Similar discordant results have also been reported for other 
cancers, such as melanoma and lung cancer [33-37]. We speculate that this discrepancy 
regarding prognostic relevance between the present and previous studies may be due 
not only to the definitions of positive staining applied, but also differences in the 
antibodies used and heterogeneous baseline characteristics. We also revealed PD-L1 
expression in TIICs and high infiltration of PD-1+ TIICs to predict favorable OS, 
which is compatible with recent reports on several cancer types [30, 38-41].  PD-1 
and PD-L1 are inhibitory immune checkpoint molecules. However, considering that 
PD-1 is expressed mainly on activated T cells and PD-L1 expression is induced by 
activated T cells, and also the association between PD-L1 expression and TIIC 
abundance including PD-1+ cells, PD-1 and PD-L1 expressions should be regarded as 
reflecting an immunoreactive state, which contributes to better OS [9]. PD-L1 positive 
tumors, which generally have abundant TIICs including PD-1+ immune cells, may 
define a subset of ESCC patients who are potential candidates for anti-PD-1 or 
anti-PD-L1 antibody therapy. However, we cannot draw a conclusion based on our 
present results as this study did not include patients receiving these agents. Ongoing 
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clinical trials of these agents are anticipated to clarify the optimal predictive 
biomarkers. 
 The number of tumor infiltrating FOXP3+ regulatory T cells, especially as 
reflected by a decreased CD8+/FOXP3+ ratio, is reportedly associated with a poor 
prognosis for several cancer types [42-45]. In addition to confirming these prior reports, 
our results clarified the prognostic significance of the CD8+/CD204+ ratio. CD204+ 
macrophages are another set of immune suppressor cells (M2 phenotype) [46], and 
marked CD204+ macrophage infiltration is reportedly associated with a malignant 
phenotype or poor survival for several cancers including ESCC [26, 47-49]. Given the 
functions of M2 macrophages, such as producing immune suppressive cytokines and 
downregulating effector T cell activity [50, 51], not only the number of CD204+ cells 
but also the balance between CD8+ and CD204+ cells must be considered. Our study is 
the first, to our knowledge, to demonstrate the positive survival impact of an increased 
CD8+/CD204+ ratio. These results suggest that regulatory T cells and M2 macrophages 
play a critical role in ESCC progression, making these cell types potentially novel 
therapeutic targets for agents which could be used in addition to immune checkpoint 
inhibitors targeting PD-1/PD-L1 signaling. 
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 Herein, TIICs in the stroma were not associated with OS. The clinical relevance 
of TIIC localization, whether in the tumor nest or the stroma, remains controversial. 
Although several reports have demonstrated the importance of the stroma [52-54], our 
results indicate that tumor nest TIICs have more clinical relevance in ESCC. Tumor 
microenvironments may differ among cancer types. The present results are 
understandable, considering that tumor nest TIICs are in direct contact with TCs. A 
report on melanoma showed lymphocytes within the tumor nests to be remarkably 
increased after immune checkpoint inhibitor treatment in patients who demonstrated a 
response, suggesting the importance of tumor nest TIICs [55]. 
 We examined for the first time the impacts of various immunological factors in 
both TCs and TIICs from a large cohort of patients with pure ESCC. Although we 
enrolled 196 patients, a considerable number, this study was performed retrospectively, 
in a single institution. A prospective study is needed to validate the present results. 
 In summary, we employed comprehensive IHC analyses in patients with ESCC. 
We demonstrated PD-L1 expression in a significant proportion of patients with ESCC, 
its association with marked infiltration of TIICs, the prognostic significance of PD-1 
and PD-L1 expressions and the impact on clinical outcomes of the balance between 
infiltrating effector cells and immune suppressor cells. Given the complex network 
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constituting anti-tumor immunity, such comprehensive analyses should be applied 
when assessing immune status in the tumor microenvironment. 
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Table 1. Clinicopathological characteristics according to PD-L1 expressions in tumor cells and tumor infiltrating immune cells 
      Total 
 
Tumor cells 
 
Tumor infiltrating immune cells 
Characteristics 
 
Number % 
 
Negative % Positive % P 
 
Negative % Positive % P 
Age 
         
0.034 
     
0.834 
 
Median (range) 65 (42-87) 
  
65 (42-83) 
 
68 (53-87) 
   
66 (42-83) 
 
65 (43-87) 
  Gender 
       
 
 
0.107 
     
0.483 
 
Male 
 
160 81.6 
 
134 83.8 26 72.2 
  
61 79.2 99 83.2 
 
 
Female 
 
36 18.4 
 
26 16.3 10 27.8 
  
16 20.8 20 16.8 
 Smoking status 
     
  
 
0.304 
  
 
 
 
0.593 
 
Non-smoker 42 21.4 
 
32 20.0 10 27.8 
  
15 19.5 27 22.7 
 
 
Smoker 
 
154 78.6 
 
128 80.0 26 72.2 
  
62 80.5 92 77.3 
 Alcohol consumption 
     
  
 
0.226 
  
 
 
 
0.340 
 
Non-drinker 26 13.3 
 
19 11.9 7 19.4 
  
8 10.4 18 15.1 
 
 
Drinker 
 
170 86.7 
 
141 88.1 29 80.6 
  
69 89.6 101 84.9 
 Location 
      
  
 
0.672 
  
 
 
 
0.311 
 
Upper 
 
24 12.2 
 
21 13.1 3 8.3 
  
9 11.7 15 12.6 
 
 
Middle 
 
78 39.8 
 
62 38.8 16 44.4 
  
26 33.8 52 43.7 
 
 
Lower 
 
94 48.0 
 
77 48.1 17 47.2 
  
42 54.5 52 43.7 
 pT 
      
  
 
0.831 
  
 
 
 
0.834 
 
2 
 
32 16.3 
 
25 15.6 7 19.4 
  
13 16.9 19 16.0 
 
 
3 
 
157 80.1 
 
129 80.6 28 77.8 
  
62 80.5 95 79.8 
 
 
4 
 
7 3.6 
 
6 3.8 1 2.8 
  
2 2.6 5 4.2 
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pN 
      
  
 
0.534 
  
 
 
 
0.858 
 
0 
 
51 26.0 
 
41 25.6 10 27.8 
  
22 28.6 29 24.4 
 
 
1 
 
59 30.1 
 
49 30.6 10 27.8 
  
24 31.2 35 29.4 
 
 
2 
 
63 32.1 
 
49 30.6 14 38.9 
  
23 29.9 40 33.6 
 
 
3 
 
23 11.7 
 
21 13.1 2 5.6 
  
8 10.4 15 12.6 
 pM 
      
  
 
0.565 
  
 
 
 
0.228 
 
0 
 
179 91.3 
 
147 91.9 32 88.9 
  
68 88.3 111 93.3 
 
 
1 
 
17 8.7 
 
13 8.1 4 11.1 
  
9 11.7 8 6.7 
 TNM stage 
     
  
 
0.916 
  
 
 
 
0.441 
 
I 
 
7 3.6 
 
6 3.8 1 2.8 
  
4 5.2 3 2.5 
 
 
II 
 
51 26.0 
 
41 25.6 10 27.8 
  
20 26.0 31 26.1 
 
 
III 
 
121 61.7 
 
100 62.5 21 58.3 
  
44 57.1 77 64.7 
 
 
IV 
 
17 8.7 
 
13 8.1 4 11.1 
  
9 11.7 8 6.7 
 Grade 
   
 
  
  
 
0.245 
  
 
 
 
0.794 
 
W/D 48 24.5 
 
43 26.9 5 13.9 
  
17 22.1 31 26.1 
 
 
M/D 127 64.8 
 
101 63.1 26 72.2 
  
52 67.5 75 63.0 
 
 
P/D 21 10.7 
 
16 10.0 5 13.9 
  
8 10.4 13 10.9 
 Lymphatic invasion 
  
 
  
  
 
0.442 
  
 
 
 
0.668 
 
Absent 
 
93 47.4 
 
78 48.8 15 41.7 
  
38 49.4 55 46.2 
 
 
Present 
 
103 52.6 
 
82 51.3 21 58.3 
  
39 50.6 64 53.8 
 Venous invasion 
  
 
  
  
 
0.145 
  
 
 
 
0.279 
 
Absent 
 
24 12.2 
 
17 10.6 7 19.4 
  
7 9.1 17 14.3 
  Present  172 87.8 
 
143 89.4 29 80.6 
  
70 90.9 102 85.7 
 
34 
 
Abbreviations: W/D, well differentiated; M/D, moderately differentiated; P/D, poorly differentiated 
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Table 2. PD–L1 expressions in tumor cells and tumor infiltrating immune cells 
 
 
Total Positive % 95% CI 
Tumor cells 196 36 18.4  13.2-24.5 
TIICs 196 119 60.7  53.5-67.6 
 
 
  TIICs P value 
(McNemar) 
  Negative Positive 
Tumor cells 
Negative 71 (44.4%) 
89 
(55.6%) 
< 0.001 
Positive 6 (16.7%) 
30 
(83.3%) 
Abbreviation: TIICs, tumor infiltrating immune cells 
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Table 3. Univariate and multivariate Cox regression analyses for overall survival 
 
Univariate analysis     
  
  
Clinicopathological factors ref 
 
HR 95% CI P 
Age > 65 ≤ 65  0.866 0.588-1.274 0.465 
Gender Female Male  0.771 0.452-1.314 0.339 
Smoking status Smoker Non-smoker  1.355 0.815-2.252 0.242 
Alcohol consumption Drinker Non-drinker  0.969 0.541-1.733 0.914 
Location lower Upper/Middle  0.893 0.606-1.315 0.566 
pT factor 4 2-3  1.600 0.587-4.361 0.358 
LN metastasis Present Absent  3.274 1.827-5.867 < 0.001 
Histological grade P/D W/D, M/D  1.857 1.073-3.213 0.027 
Lymphatic invasion Present Absent  2.180 1.454-3.269 < 0.001 
Venous invasion Present Absent   1.628 0.848-3.125 0.143 
Immunological factors ref   HR 95% CI P 
PD-L1 (TCs) Positive Negative  0.493 0.270-0.901 0.022 
PD-L1 (TIICs) Positive Negative  0.670 0.455-0.986 0.042 
CD4 High Low  0.786 0.535-1.154 0.219 
CD8 High Low  0.668 0.454-0.984 0.041 
FOXP3 High Low  1.279 0.868-1.885 0.213 
PD-1 High Low  0.656 0.445-0.967 0.033 
CD68 High Low  0.877 0.597-1.289 0.505 
CD204 High Low  1.239 0.842-1.824 0.276 
CD8+/FOXP3+ High Low  0.601 0.406-0.890 0.011 
CD8+/CD204+ High Low  0.641 0.435-0.946 0.025 
FOXP3+/CD4+ High Low  1.509 1.023-2.225 0.038 
CD204+/CD68+ High Low   1.219 0.828-1.795 0.315 
Multivariate analysis#       
Immunological 
factors   ref   HR 95% CI P 
PD-L1 (TCs) Positive Negative  0.461 0.246-0.864 0.016 
PD-L1 (TIICs) Positive Negative  0.590 0.394-0.884 0.010 
CD4 High Low  0.787 0.527-1.175 0.599 
CD8 High Low  0.693 0.456-1.052 0.085 
FOXP3 High Low  1.267 0.837-1.918 0.263 
PD-1 High Low  0.579 0.387-0.865 0.008 
CD68 High Low  1.009 0.668-1.526 0.964 
CD204 High Low  1.299 0.866-1.964 0.206 
CD8+/FOXP3+ High Low  0.617 0.413-0.923 0.019 
CD8+/CD204+ High Low  0.650 0.439-0.962 0.031 
FOXP3+/CD4+ High Low  1.381 0.922-2.067 0.117 
CD204+/CD68+ High Low   1.106 0.742-1.648 0.621 
Abbreviations: HR, hazard ratio; CI, confidence interval; LN, lymph node; W/D, well differentiated; 
M/D, moderately differentiated; P/D, poorly differentiated; TCs, tumor cells; TIICs, 
tumor-infiltrating immune cells 
#adjusted for age, gender, smoking habit, alcohol consumption, pT factor, LN metastasis, histological 
grade, lymphatic invasion, and venous invasion 
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Figure 1. Representative images of PD-L1 expression 
(A) Tumor cells are positive for membranous staining of PD-L1. (B) H&E image of the serial section 
in (A). (C) TIICs are positive for PD-L1. (D) H&E image of the serial section in (C). Bar: 50μm. 
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Figure 2. Associations between PD-L1 expression and tumor infiltrating immune cells 
(A) Density of each immune cell type according to PD-L1 expression in tumor cells. (B) Density of 
each immune cell type according to PD-L1 expression in TIICs. (C) Immune cell ratios according to 
PD-L1 expression in tumor cells. (D) Immune cell ratios according to PD-L1 expression in TIICs. 
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Figure 3. Kaplan-Meier curves according to PD-L1 expression, with 5-year survival rate and the 
log-rank test for overall survival 
(A) PD-L1 expression in tumor cells. (B) PD-L1 expression in TIICs. (C) Utility of combining 
PD-L1 expressions in tumor cells and TIICs; group 1 (n = 30): Both tumor cells and TIICs are 
PD-L1 positive, group 2 (n = 95): either tumor cells or TIICs are PD-L1 positive, group 3 (n = 71): 
both tumor cells and TIICs are PD-L1 negative. 
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Figure 4. Kaplan-Meier curves according to TIIC ratios, with 5-year survival rate and the log-rank 
test for overall survival 
(A) CD8+/FOXP3+ ratio. (B) CD8+/CD204+ ratio. (C) FOXP3+/CD4+ ratio (D) CD204+/CD68+ ratio. 
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Supplementary Figure 1. Hazard ratio for OS according to the cut-off value for PD–L1 expression in 
tumor cells 
A sensitivity test was performed using the hazard ratio for OS with the cut-off values for PD–L1 
expression in cancer cells according to the proportions of tumor cells with PD–L1 membrane 
staining scored 1%, 5%, 10%, 20% and 30%. The minimum hazard ratio was obtained when the 
cut-off value of 1% was adopted (0.493, 95% CI: 0.270-0.901, P = 0.022). 
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Supplementary Figure 2. Representative IHC images of PD-L1 expression and each tumor 
infiltrating immune cell type in serial sections. 
(A) PD-L1 positive tumor. (B) CD4+ cells. (C) CD8+ cells. (D) FOXP3+ cells. (E) PD-1+ cells. (F) 
CD68+ macrophages. (G) CD204+ macrophages. Bar: 100μm. 
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Supplementary Figure 3. Kaplan-Meier curves according to each of the TIIC types with 5-year 
survival rate and the log-rank test for OS 
(A) CD4+ cells. (B) CD8+ cells. (C) FOXP3+ cells. (D) PD-1+ cells. (E) CD68+ cells. (F) CD204+ 
cells.  
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Supplementary Figure 4. Survival analyses according to TIICs in the tumor stroma. 
Kaplan-Meier curves of OS for (A) CD8+/FOXP3+ ratio, (B) CD8+/CD204+ ratio, and (C) PD-1+ 
cells. (D) Multivariate Cox regression analyses for OS. 
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Supplementary Material 1. Antibodies and immunohistochemical assays 
Abbreviations: M/W, microwave; EDTA, ethylenediaminetetraacetic acid; DAB, diaminobenzidine 
 
For FOXP3, and PD-L1, slides were dewaxed and rehydrated in distilled water, and endogenous peroxidase activity was then blocked by immersion in 
3% hydrogen peroxide in methanol for 10 minutes. After antigen retrieval, the slides were incubated overnight at 4 °C with each primary antibody. The 
slides were then further incubated with anti-mouse secondary antibody (EnVision+ System-HRP Labelled Polymer Anti-mouse, Dako, Tokyo, Japan) for 
FOXP3 and PD-1 or anti-rabbit secondary antibody (EnVision+ System-HRP Labelled Polymer Anti-rabbit, Dako) for PD-L1, and staining was detected 
using a standard diaminobenzidine procedure. Finally, the sections were counterstained with hematoxylin. 
  
Marker Source Type Clone Procedure Dilution Antigen retrieval Visualization Manufacturer 
PD-L1 Rabbit Monoclonal E1L3N Manual 1:400 M/W (95°C, 10 min.),  Citrate buffer (pH 6.0) Standard DAB procedure 
Cell Signaling Technology 
(Cambridge, UK) 
CD4 Rabbit Monoclonal SP35 Autostainer Ready-to-use Heat (95°C, 64 min.),  CC1: EDTA buffer (pH 8.5) iVIEW DAB Detection Kit 
Ventana 
(Tucson, AZ, USA) 
CD8 Rabbit Monoclonal SP57 Autostainer Ready-to-use Heat (95°C, 64 min.),  CC1: EDTA buffer (pH 8.5) 
ultra View Universal DAB 
Detection Kit Ventana 
FOXP3 Mouse Monoclonal 236A/E7 Manual 1:100 A/C (121°C, 10 min.),  Citrate buffer (pH 6.0) Standard DAB procedure 
Abcam 
(Cambridge, UK) 
PD-1 Mouse Monoclonal EH33 Manual 1:200 M/W (95°C, 20 min.),  EDTA buffer (pH 9.0) Standard DAB procedure Cell Signaling Technology 
CD68 Mouse Monoclonal KP-1 Autostainer Ready-to-use Heat (95°C, 64 min.),  CC1: EDTA buffer (pH 8.5) 
ultra View Universal DAB 
Detection Kit Ventana 
CD204 Mouse Monoclonal SRA-E5 Autostainer 1:400 Heat (95°C, 64 min.),  CC1: EDTA buffer (pH 8.5) iVIEW DAB Detection Kit 
Transgenic 
(Kumamoto, Japan) 
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